NCT05756907 2026-02-03
Combination of SON-1010 (IL12-FHAB) and Atezolizumab in Patients With Platinum-resistant Ovarian Cancer
Sonnet BioTherapeutics
Phase 1/2 Terminated
Clinical Trials
60 trialsNCT05070247 2026-01-22
A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
Takeda
Phase 1/2 Terminated
NCT05262530 2026-01-21
Safety and Preliminary Efficacy Trial of BNT142 in Patients With CLDN6-positive Solid Tumors
BioNTech SE
Phase 1/2 Terminated
NCT04284488 2026-01-08
Dose-escalation Study of APG-1387 and Toripalimab in Solid Tumors
Ascentage Pharma Group Inc.
Phase 1/2 Terminated
NCT06198426 2025-12-30
A Study of IBI3004 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1/2 Terminated
NCT06391775 2025-12-26
Trial to Assess the Safety and Preliminary Efficacy of GEN1055 on Malignant Solid Tumors as Monotherapy and as Combination Therapy
Genmab
Phase 1/2 Terminated
NCT04972110 2025-10-30
ATTACC
Repare Therapeutics
Phase 1/2 Terminated
NCT05326035 2025-10-02
A Study of WJ05129 in Advanced Malignant Solid Tumors
Suzhou Junjing BioSciences Co., Ltd.
Phase 1/2 Terminated
NCT05821777 2025-09-25
A Study to Evaluate Safety, Tolerability and Preliminary Activity of LB101 in Participants With Advanced Solid Tumors
Centessa Pharmaceuticals plc
Phase 1/2 Terminated
NCT06226766 2025-09-10
JSKN033 in Patients With Advanced or Metastatic Solid Malignant Tumors
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 1/2 Terminated
NCT05109442 2025-08-20
Study to Assess AFM24 in Combination With Atezolizumab in Selected Advanced/Metastatic EGFR-expressing Cancers
Affimed GmbH
Phase 1/2 Terminated
NCT01309490 2025-07-29
Phase I/II Study of Ribavirin Given as Monotherapy in Solid Tumour Cancer Patients
Jewish General Hospital
Phase 1/2 Terminated
NCT05714553 2025-07-18
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
NuCana plc
Phase 1/2 Terminated
NCT04259450 2025-07-17
Study to Assess AFM24 in Advanced Solid Cancers
Affimed GmbH
Phase 1/2 Terminated
NCT04455620 2025-07-02
BNT151 as a Monotherapy and in Combination With Other Anti-cancer Agents in Patients With Solid Tumors
BioNTech SE
Phase 1/2 Terminated
NCT05435339 2025-04-22
A Study to Evaluate Safety, Tolerability, and Preliminary Effect of the GEN1053 Antibody on Malignant Solid Tumors as Monotherapy
Genmab
Phase 1/2 Terminated
NCT04084366 2025-03-26
Phase 1/2 Study of OBI-999 in Patients With Advanced Solid Tumors
OBI Pharma, Inc
Phase 1/2 Terminated
NCT05559541 2025-02-19
Study of AK119 Combined With AK104 in Patients With Advanced Solid Tumors
Akeso
Phase 1/2 Terminated
NCT05580770 2025-02-17
Mirdametinib + BGB-3245 in Advanced Solid Tumors
SpringWorks Therapeutics, Inc.
Phase 1/2 Terminated
NCT04492033 2025-01-27
A Study of CTX-009 (ABL001) in Combination With Irinotecan or Paclitaxel in Advanced or Metastatic Solid Tumor Patients
Handok Inc.
Phase 1/2 Terminated
NCT03717415 2024-12-27
A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors
Deciphera Pharmaceuticals, LLC
Phase 1/2 Terminated
NCT05500508 2024-12-24
Oral AMXT 1501 Dicaprate in Combination With IV DFMO
Aminex Therapeutics, Inc.
Phase 1/2 Terminated
NCT06524804 2024-12-18
A Phase Ib/II Study of BY101298 , an Oral DNA-PK Inhibitor, Combined with Radiotherapy in Patients with Malignant Solid Tumors
Chengdu Baiyu Pharmaceutical Co., Ltd.
Phase 1/2 Terminated
NCT03316638 2024-12-10
Ulysse
Pierre Fabre Medicament
Phase 1/2 Terminated
NCT03379259 2024-10-26
Study of BGB-A333 Alone and in Combination With Tislelizumab in Advanced Solid Tumors
BeiGene
Phase 1/2 Terminated
NCT03592264 2024-10-15
A Phase I/II Study of OBI-3424 in Subjects with Advanced Solid Tumors
OBI Pharma, Inc
Phase 1/2 Terminated
NCT05824455 2024-09-05
A Clinical Study of IMP4297 Capsule (JS109) Combined With Irinotecan in the Treatment of Advanced Malignant Solid Tumors
Shanghai Jun Pai Ying Shi Therapeutics Co., Ltd.
Phase 1/2 Terminated
NCT04957290 2024-06-18
A Study of NOX66 and External Beam Radiotherapy in Patients With Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors
Noxopharm Limited
Phase 1/2 Terminated
NCT03319537 2024-05-23
Pevonedistat Alone and in Combination With Chemotherapy in Patients With Mesothelioma
Memorial Sloan Kettering Cancer Center
Phase 1/2 Terminated
NCT01898156 2024-04-25
Two-Part, Open-Label, Multi-Center, Phase 1/2 Study of BIW-8962 as Monotherapy in Subjects With Lung Cancer
Kyowa Kirin Co., Ltd.
Phase 1/2 Terminated
NCT05148533 2024-04-15
A Study of Single Drug TJ011133 and Toripalimab Combine Treatment for Advanced Solid Tumor
TJ Biopharma Co., Ltd.
Phase 1/2 Terminated
NCT03573544 2024-02-22
This Study is to Evaluate Safe and Effective Treatment Dose of OBI-888 in Patients With Locally Advanced or Metastatic Solid Tumors.
OBI Pharma, Inc
Phase 1/2 Terminated
NCT03393858 2024-02-07
Combination of Immunotherapy and Hyperthermia in Advanced Malignant Mesothelioma
Capital Medical University
Phase 1/2 Terminated
NCT05430555 2024-02-07
IMAG1NE
T-knife GmbH
Phase 1/2 Terminated
NCT05920408 2023-11-08
Study to Assess EXS21546 in Combination in Patients With Advanced Solid Tumours
Exscientia AI Limited
Phase 1/2 Terminated
NCT05255484 2023-10-25
Study of LM-108 as a Single Agent or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumours
LaNova Medicines Limited
Phase 1/2 Terminated
NCT04552704 2023-08-02
CD24Fc for the Treatment of Immune Related Adverse Events in Patients With Advanced Solid Tumors, TIRAEC Study
University of California, Davis
Phase 1/2 Terminated
NCT04471415 2023-06-12
Study to Investigate DRP-104 in Adults With Advanced Solid Tumors
Dracen Pharmaceuticals, Inc.
Phase 1/2 Terminated
NCT03233724 2023-05-31
Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT05010525 2023-03-17
REACH
Antengene Corporation
Phase 1/2 Terminated
NCT05008445 2023-03-09
Study of LM-102 in Patients With Advance Solid Tumors
LaNova Medicines Limited
Phase 1/2 Terminated
NCT04372706 2022-12-13
RTX-240 Monotherapy and in Combination With Pembrolizumab
Rubius Therapeutics
Phase 1/2 Terminated
NCT02859415 2022-04-05
Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT03515551 2022-03-11
Safety and Efficacy of IMCnyeso in Advanced NY-ESO-1 and/or LAGE-1A Positive Cancers
Immunocore Ltd
Phase 1/2 Terminated
NCT02408016 2021-09-13
Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma
Fred Hutchinson Cancer Center
Phase 1/2 Terminated
NCT03277352 2021-07-22
INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
Incyte Corporation
Phase 1/2 Terminated
NCT01433991 2021-06-08
A Study of E7050 in Combination With E7080 in Participants With Advanced Solid Tumors (Dose Escalation) and in Participants With Recurrent Glioblastoma or Unresectable Stage III or Stage IV Melanoma After Prior Systemic Therapy (Expansion Cohort and Phase 2)
Eisai Inc.
Phase 1/2 Terminated
NCT02587962 2021-01-14
Dose-escalation Study of Birinapant and Pembrolizumab in Solid Tumors
Medivir
Phase 1/2 Terminated
NCT02380677 2020-06-09
Phase 1/2a Dose-Escalation Study of CRLX301 in Patients With Advanced Solid Tumors
Lumos Pharma
Phase 1/2 Terminated
NCT02541604 2020-02-25
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors
Hoffmann-La Roche
Phase 1/2 Terminated